GlassScriptPhysician profile
Zachary Decant
NPI 1417343922
$1,992.72
in general payments reported to CMS, 2019-2025
30 companies · $864 in 2025
The $864 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $95.18 · 2022: $161 · 2023: $293 · 2024: $579 · 2025: $864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,736.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,736.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $315.04 | 2022-2025 | Ubrelvy, Qulipta |
| Lilly USA, LLC | $187.14 | 2023-2025 | Kisunla, Amyvid, Emgality |
| Ucb, INC. | $178.57 | 2023-2025 | Zilbrysq, Nayzilam, Rystiggo |
| Alexion Pharmaceuticals, INC. | $155.66 | 2024-2025 | Ultomiris |
| Genentech USA, INC. | $118.80 | 2022-2025 | Ocrevus, Ocrevus Zunovo |
| Novartis Pharmaceuticals Corporation | $102.51 | 2024-2025 | |
| Eisai INC. | $93.88 | 2023-2025 | |
| Merz Pharmaceuticals, LLC | $78.43 | 2023-2025 | Xeomin, Inbrija |
| Banner Life Sciences, LLC | $68.22 | 2022-2024 | |
| Pfizer INC. | $62.91 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $52.73 | 2024-2025 | Austedo Xr, Austedo Xr |
| Tanabe Pharma America, INC. | $52.71 | 2025 | Radicava |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $47.44 | 2023-2025 | Rexulti |
| Amneal Pharmaceuticals LLC | $45.86 | 2021-2025 | Crexont |
| Microtransponder, INC. | $40.21 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $38.36 | 2024-2025 | Uplizna |
| Neuropace, INC. | $34.94 | 2024 | |
| Vanda Pharmaceuticals INC. | $33.37 | 2025 | Ponvory |
| Kyowa Kirin, INC. | $31.05 | 2021 | |
| Supernus Pharmaceuticals, INC. | $29.08 | 2022 | |
| Insightec,INC | $26.46 | 2022 | |
| Sk Life Science, INC. | $25.04 | 2024 | |
| Ge Healthcare | $24.56 | 2024 | |
| Acadia Pharmaceuticals INC | $24.53 | 2021 | |
| Avanir Pharmaceuticals, INC. | $23.08 | 2022 | |
| Biogen, INC. | $22.11 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.98 | 2025 | Caplyta |
| Argenx US, INC. | $21.63 | 2024 | Vyvgart Hytrulo, Vyvgart |
| Axsome Therapeutics, INC. | $19.29 | 2025 | Symbravo |
| Tg Therapeutics, INC. | $17.13 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zachary Decant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.